- Learn More
We are fortunate to advise world-class, industry-leading companies, helping them tackle novel, complex issues and push the boundaries of technological progress. Our ability and confidence to go to trial is our core strength; our deep bench of experienced trial lawyers represents companies in their most significant matters, helping them protect their intellectual property and launch products. Our lawyers pair extensive experience in the courtroom and the boardroom with a thorough understanding of science and technology.
Paul, Weiss secured an appellate victory for Tokyo-based drug manufacturer Chugai Pharmaceutical Co. Ltd in a dispute regarding two Chugai patents for a simpler, less costly method of purifying antibodies. The U.S. Court of Appeals for the Federal Circuit rejected a major pharmaceutical company’s appeals of two Patent Trial and Appeal Board rulings that upheld the validity of Chugai’s patents. A three-judge Federal Circuit panel found that the pharmaceutical company lacked standing to appeal because it had failed to prove it would suffer a concrete and particularized injury in fact from the PTAB’s final written decisions in the two IPRs below. The panel noted that the pharmaceutical company’s argued evidence for standing did not cover the period when the appeal began, and also did not “establish with sufficient likelihood that the processes used to prepare [its] product would infringe Chugai’s patents.”
The Paul, Weiss team included litigation partners Steven Baughman, Jennifer Wu and Eric Stone, counsel Megan Raymond and Jenny Wu.